Manufacture of basic pharmaceutical products and pharmaceutical preparations
Nationally 1.50% of enterprises go bankrupt within five years; this failure rate is higher than that of 92% of the 88 NACE divisions. The median bankruptcy probability in NACE division 21 is 0.6%, against 0.5% nationally, over 263 scored companies.
Key figures for NACE division 21
fiscal year 2025 · median over 174 filed annual accountsRegional split
by region · 143 of 149 enterprises with a registered office on fileRecent bankruptcies in this sector
5| Date | Company |
|---|---|
| 24-04-2026 | San'Up
BE 0693.818.729 |
| 27-10-2025 | Quantoom Biosciences
BE 0744.643.858 |
| 02-09-2025 | EXOTHERA
BE 0744.643.660 |
| 14-06-2024 | Mithra Pharmaceuticals
BE 0466.526.646 |
| 14-06-2024 | GRAFTYS
BE 0676.661.805 |
Geographic distribution
by province · based on the establishment addressHow these figures are counted
Enterprises are counted by their primary NACE; establishment units are not counted. Counted in the KBO's NACE 2025 nomenclature, the one in which code 21201 exists.
Bankruptcies and the failure rate are attributed by each company's current primary NACE, not the NACE at the time of bankruptcy (which the gazette does not record).
The comparison with the country and with the other NACE divisions comes from a nightly overview of every division, each counted in the nomenclature in which it exists. A standing such as "higher than 80%" counts the other divisions that have the figure. The bankruptcy probability is the median of our nightly score over the division's companies that have one; the count is stated.
The key figures cover the whole NACE division 21, not NACE 21201 on its own: there are too few filed annual accounts per five-digit code to compute them separately. Medians over NBB annual accounts, all schema types combined.